<DOC>
	<DOCNO>NCT02324452</DOCNO>
	<brief_summary>In study determine whether rate severe toxicity associate fluoropyrimidine treatment ( capecitabine 5-fluorouracil ) significantly diminish individualized dose fluoropyrimidines base upfront genotypic assessment dihydropyrimidine dehydrogenase ( DPD ) deficiency . In addition genotyping , DPD phenotype patient determine measure baseline dihydrouracil/uracil ( DHU/U ) ratio , order investigate whether phenotype-guided treatment improve patient safety . In subgroup patient , phenotyping method test : measure plasma level uracil uracil test dose uracil breath test dose [ 2-13C ] -labeled uracil . To validate test , phenotyping result compare result DPD activity assay ( measure DPD enzyme activity peripheral blood mononuclear cell ) , consider gold standard measure DPD phenotype .</brief_summary>
	<brief_title>Safety , Feasibility Cost-effectiveness Genotype-directed Individualized Dosing Fluoropyrimidines</brief_title>
	<detailed_description />
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Pathologically confirmed malignancy treatment fluoropyrimidine consider patient 's best interest 2 . Age â‰¥ 18 year 3 . Able willing give write informed consent 4. WHO performance status 0 , 1 2 5 . Life expectancy least 12 week 6 . Able swallow retain oral medication 7 . Able willing undergo blood sample pharmacogenetic phenotyping analysis 8 . Minimal acceptable safety laboratory value ( ANC , platelet count , hepatic function , renal function ) Additional inclusion criterion patient subgroup study : 1 . Able willing undergo blood sample breath sample several time point 2 . Able willing receive uracil test dose assay 3 . Able willing receive [ 213C ] label uracil breath test 1 . Prior treatment fluoropyrimidines 2 . Patients know substance abuse , psychotic disorder , and/or disease expect interfere study patient 's safety 3 . Women pregnant breast feed 4 . Both men woman refuse use reliable contraceptive method throughout study ( adequate contraceptive method : condom , sterilization , barrier contraceptive measure preferably combination condom ) 5 . Patients homozygous polymorphic genotype compound heterozygous genotype DPYD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>